Radiation

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Retrieved on: 
Monday, July 31, 2023
Lung cancer, LAG-3, University of Frankfurt Institute for Social Research, Overalls, ESMO, Survival, Cancer, ASX, Oncology, NSCLC, Merck & Co., Phase II, IMM, Congress, Radiation, Autoimmune disease, Merck, European Society for Medical Oncology, Research, Pembrolizumab, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry

SYDNEY, AUSTRALIA, July 31, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that data from its TACTI-002 Phase II trial evaluating the chemo-free combination of eftilagimod alpha (“efti”) and KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Rahway, NJ, USA) anti-PD-1 therapy, in 1st line non-small cell lung cancer (1L NSCLC) has been accepted for a Mini Oral presentation at the 2023 European Society for Medical Oncology (ESMO) Congress that will be held in Madrid, Spain from 20-24 October 2023. The presentation will include more mature overall survival data, following on from the data announced on 17 May 2023.

Key Points: 
  • The presentation will include more mature overall survival data, following on from the data announced on 17 May 2023 .
  • Additionally, data from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF evaluating efti in conjunction with anti-PD-1 therapy (pembrolizumab) and doublet chemotherapy (carboplatin/pemetrexed) in non-squamous 1L NSCLC, has been accepted for a poster presentation.
  • Also, a Trial in Progress poster for the EFTISARC-NEO investigator-initiated Phase II trial evaluating efti with pembrolizumab and radiotherapy in soft tissue sarcoma will be presented.
  • Title: Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)
    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Retrieved on: 
Friday, July 28, 2023
Arm, Sarcoma, MHC, Cancer, ASX, STS, B cell, Melanoma, Government, IMM, Incidence, Polish Medical Association, MHC class II, Radiation, Maria Sklodowska-Curie National Research Institute of Oncology, Patient, Soft, Autoimmune disease, Neoplasm, American Cancer Society, Phase, Pembrolizumab, Pharmaceutical industry

SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed in EFTISARC-NEO, the Phase II investigator-initiated trial of eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with radiotherapy and the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for patients with soft tissue sarcoma. This chemo-free trial is the first to evaluate efti in a neoadjuvant setting.

Key Points: 
  • This chemo-free trial is the first to evaluate efti in a neoadjuvant setting.
  • Soft tissue sarcoma (STS), an orphan disease, represents a high unmet medical need with a poor prognosis.
  • The trial’s Principal Investigators are Dr. Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO.
  • New information arising from this innovative trial may further broaden the future clinical development of efti and, in the end, bring even greater benefit to patients.”

CHOP and Penn Medicine Researchers Develop "In Vivo" RNA-based Gene Editing Model for Blood Disorders

Retrieved on: 
Thursday, July 27, 2023
Nanoparticle, Bone marrow, Doctor of Philosophy, Bangladesh Technical Education Board, COVID-19 vaccine, MD, Patient, Division, Risk, Thomas, Perelman School of Medicine at the University of Pennsylvania, LNP Media Group, CD117, DSM-IV codes, Infection, Disease, Children's Hospital of Philadelphia, Tissue, Hematologic disease, BS, University, Pediatrics, Therapy, CHOP, Hematology, Gene editing, Biomedical Research, Mutation, Research, Penn Institute for Urban Research, DOI, Hospital, HSC, NIH, Vaccine, Hematopoietic stem cell, Stem cell, COVID-19, Philadelphia, Cell, Child, Antibody, Messenger, Blood, Immune system, LNP, Radiation, Doctor of Pharmacy, Cell death, PUMA, SCID, Sickle cell disease, RNA, Penn, Health, Dicarboxylic acid, Dentistry, Pharmaceutical industry, Science

PHILADELPHIA, July 27, 2023 /PRNewswire/ -- In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body. If translated into the clinic, this approach could expand access and reduce the cost of gene therapies for blood disorders, many of which currently require patients receive chemotherapy and a stem cell transplant. The findings were published today in the journal Science.

Key Points: 
  • This approach could expand access and reduce the cost of gene therapies for blood disorders.
  • A targeted mRNA-encoded genomic editing methodology could lead to controlled expression, high editing efficacy, and potentially safer in vivo genomic modification compared to currently available technologies."
  • In patients with non-malignant hematopoietic disorders like sickle cell disease and immunodeficiency disorders, these blood cells don't function correctly because they carry a genetic mutation.
  • First, the researchers tested CD117/LNP encapsulating reporter mRNA to show successful in vivo mRNA expression and gene editing.

Proprio Raises $43M Series B Funding to Fuel Commercialization

Retrieved on: 
Thursday, July 27, 2023
Partnership, Radiation, Surgeon, Anatomy, 3D, Intelligence, Patient, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical device, Dentistry, Paradigm, Motu proprio

SEATTLE, July 27, 2023 /PRNewswire/ -- Proprio, a Seattle-based surgical technology company, today announced that it has secured $43 million in Series B funding from new and existing investors. The capital fuels commercialization to address significant demand for Proprio's AI-driven surgical navigation platform in the US and overseas.

Key Points: 
  • SEATTLE, July 27, 2023 /PRNewswire/ -- Proprio , a Seattle-based surgical technology company, today announced that it has secured $43 million in Series B funding from new and existing investors.
  • The capital fuels commercialization to address significant demand for Proprio's AI-driven surgical navigation platform in the US and overseas.
  • Paradigm harnesses the power of light field technology and artificial intelligence to generate a real-time 3D visualization of surgery.
  • Together, these milestones are a testament to the unparalleled capabilities of the Proprio Paradigm and its potential to revolutionize surgery."

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Thursday, July 27, 2023
Radiation, Neoplasm, Immunotherapy, Autoimmunity, Prescription Drug User Fee Act, Ira Pastan, Patient, Autoimmune disease, PD-1, Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, PD-L1, FC, Food, Safety, Pharmaceutical industry

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”). These results demonstrate a deepening of response over time, resulting in substantially higher complete response rates than previously reported. Furthermore, responses continue to remain durable over time with the median duration of response not yet reached in either group. Results determined by independent central review by treatment group were as follows:

Key Points: 
  • “We are excited to see the substantial increases in the rate of patients experiencing a complete response of their cSCC tumors with further cosibelimab treatment in both our locally advanced and metastatic pivotal trials,” said James Oliviero, President and Chief Executive Officer of Checkpoint.
  • Mr. Oliviero continued, “Unlike PD-1 inhibitors, cosibelimab does not interrupt the body’s PD-1/PD-L2 pathway, which we believe results in cosibelimab’s low rates of autoimmunity.
  • The application is filed and under review with a Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024.
  • Checkpoint plans to present these updated results at an upcoming medical conference.

World Renowned Biomedical Professor Jonathan Lakey Joins CancerVAX Board of Advisors

Retrieved on: 
Thursday, July 27, 2023
Meritorious Service Medal (China), BS, Radiation, University, Royal college, Diabetes, Meritorious Service Medal, Physician, Edmonton protocol, Enzyme, University of California, Irvine, Cancer, Research, Central Waqf Council, Doctor of Philosophy, Biomedical engineering, MS, Patient, Organ transplantation, Surgeon, B cell, Transplant, Royal College of Physicians and Surgeons of Canada, Disease, Dentistry, Science, LEHI

Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.

Key Points: 
  • Dr. Lakey graduated from the University of Alberta with a BS, MS and PhD and received post-doctoral training in Indianapolis and Seattle.
  • Dr. Lakey is currently the Professor of Surgery and Biomedical Engineering and the Director of the Clinical Islet Program at University of California Irvine.
  • CancerVAX CEO Ryan Davies said, “We are honored to have Dr. Lakey join our Board of Advisors.
  • This is a noble cause and I am honored to have a part in the exciting work CancerVAX is doing”, said Dr. Lakey.

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Retrieved on: 
Thursday, July 27, 2023
Vaccine, Neutropenia, VRE, Fungal infection, Eravacycline, Infection, Fever, New Drug Application, MRSA, Gram-negative bacteria, NDA, Urinary tract infection, First Affiliated Hospital of Xinjiang Medical University, Hematopoietic stem cell transplantation, Soochow University, Incidence, MDR, Radiation, HKEX, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, IgA nephropathy, CRE, NMPA, Pharmaceutical industry, Mount Everest

SHANGHAI, July 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company.

Key Points: 
  • "The commercialization of XERAVA® in China is a significant milestone for Everest as a company, as this marks the beginning of Everest as a commercial-stage biopharma company.
  • I want to thank everyone involved in bringing XERAVA® to a successful launch," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
  • "After the commercial launch, we will accelerate patient access to XERAVA® with a lean commercial team, following a highly efficient commercial strategy.
  • The launch of eravacycline in China will help doctors tackle the challenges of clinical drug resistance."

Lockheed Martin Selected to Develop Nuclear-Powered Spacecraft

Retrieved on: 
Wednesday, July 26, 2023
Human, Radiation, Travel, DARPA, BWXT, Moon, Spacecraft, Unitary state, Lockheed, DRACO, NTP, Government, HALEU, Chemical substance, BWX Technologies, NASA, Lockheed Martin Space, NYSE, LMT, Jet fuel, Transport, Lithium, Mars

DENVER, July 26, 2023 /PRNewswire/ -- Lockheed Martin [NYSE: LMT] has won a contract from the Defense Advanced Research Projects Agency (DARPA) to develop and demonstrate a nuclear-powered spacecraft under a project called Demonstration Rocket for Agile Cislunar Operations (DRACO). The project will represent a rapid advancement in propulsion technology to benefit exploration and national defense.

Key Points: 
  • DENVER, July 26, 2023 /PRNewswire/ -- Lockheed Martin [NYSE: LMT] has won a contract from the Defense Advanced Research Projects Agency (DARPA) to develop and demonstrate a nuclear-powered spacecraft under a project called Demonstration Rocket for Agile Cislunar Operations (DRACO).
  • Reducing transit time is vital for human missions to Mars to limit a crew's exposure to radiation," said Kirk Shireman, vice president of Lunar Exploration Campaigns at Lockheed Martin Space.
  • Lockheed Martin has partnered with BWX Technologies to develop the nuclear reactor and produce the HALEU fuel.
  • Lockheed Martin has also invested heavily in cryogenic hydrogen storage and transfer.

Leading Companies in the Global Stereotactic Surgery Devices Market, Including CyberKnife and PBRT, Expected to Contribute to Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 26, 2023
Surgery, Health, Medical Devices, Cyberknife, PBRT, COVID-19, Liver, Cancer, Research, USD, Government, Organization, Radiation, Hospital, LINAC, Investment, Patient, Disease, Diagnosis, Mortality, Growth, Pharmaceutical industry, Breast

The global stereotactic surgery devices market size is projected to reach USD 34.47 billion by 2030, expanding at 3.9% CAGR from 2023 to 2030.

Key Points: 
  • The global stereotactic surgery devices market size is projected to reach USD 34.47 billion by 2030, expanding at 3.9% CAGR from 2023 to 2030.
  • Increasing demand for minimally invasive surgeries, new product launches, and increasing investments in radiotherapy to improve oncology treatment are key factors driving the demand for stereotactic surgery devices industry.
  • This is also leading to stereotactic surgery devices replacing conventional invasive procedures.
  • The COVID-19 pandemic negatively impacted the market and led to a sharp fall in sales of stereotactic surgery devices.

BWXT to Provide Nuclear Reactor Engine and Fuel for DARPA Space Project

Retrieved on: 
Wednesday, July 26, 2023
Contracts, Nuclear, Energy, Technology, Defense, Satellite, Science, Government Technology, Engineering, Automotive Manufacturing, Manufacturing, Other Science, Radiation, Partnership, BWXT, Moon, Spacecraft, Form 10-K, Lockheed Martin, Multimedia, Risk, Lockheed, DRACO, Government, HALEU, NYSE, DARPA, BWX Technologies, Lockheed Martin Space, Security (finance), Annual report, Lithium, Uranium mining

BWX Technologies, Inc. (NYSE: BWXT) today announced that its reactor and fuel will be key components in the world’s first demonstration spacecraft using nuclear thermal propulsion.

Key Points: 
  • BWX Technologies, Inc. (NYSE: BWXT) today announced that its reactor and fuel will be key components in the world’s first demonstration spacecraft using nuclear thermal propulsion.
  • View the full release here: https://www.businesswire.com/news/home/20230726525537/en/
    DARPA has selected BWXT and Lockheed Martin to produce a nuclear-powered spacecraft.
  • “This partnership with Lockheed Martin working for DARPA adds another important dimension to BWXT’s already-impressive line-up of nuclear reactor designs for commercial and defense applications.”
    “These more powerful and efficient nuclear thermal propulsion systems can provide faster transit times between destinations.
  • BWXT cautions that this release contains forward-looking statements, including statements relating to the performance, scope and timing of the nuclear thermal propulsion reactor and fuel contract.